In the standalone financial statements for the fiscal year ending March 2026, dividend income of JPY 48,340 million was recognized as non-operating income due to dividends paid by the consolidated subsidiary Sumitomo Pharma Switzerland GmbH.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-03-25","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4506-20260325-01.pdf","jir_short_summary":"In the standalone financial statements for the fiscal year ending March 2026, dividend income of JPY 48,340 million was recognized as non-operating income due to dividends paid by the consolidated subsidiary Sumitomo Pharma Switzerland GmbH.","jir_summary":"### Details of Non-Operating Income\nSumitomo Pharma Co., Ltd. announced that in its standalone financial statements (Japanese GAAP) for the fiscal year ending March 2026 (April 1, 2025 to March 31, 2026), it recognized dividend income of JPY 48,340 million as non-operating income, resulting from dividends paid by its consolidated subsidiary Sumitomo Pharma Switzerland GmbH.\n\n### Impact on Financial Results\nThis dividend income is recorded in the standalone financial statements and is eliminated in the consolidated financial statements; therefore, it has no impact on consolidated earnings.","jir_financial_highlights":"Dividend Income Received: JPY 48,340 million (Unknown)","jir_category":"","jir_hashtags":"#SumitomoPharma, #FinancialStatements, #NonOperatingIncome","jir_key_figures":"Dividend Income Received: JPY 48,340 million (Fiscal Year Ending March 2026, Standalone Financial Statements)\nImpact on Consolidated Earnings: None\nPeriod Covered: April 1, 2025 to March 31, 2026","jir_meta_title":"Sumitomo Pharma Recognizes JPY 48,340 Million Dividend Income as Non-Operating Income in Standalone Financial Statements for Fiscal Year Ending March 2026","jir_meta_description":"Sumitomo Pharma recognized dividend income of JPY 48,340 million as non-operating income in its standalone financial statements for the fiscal year ending March 2026 due to dividends paid by consolidated subsidiary Sumitomo Pharma Switzerland GmbH. There is no impact on consolidated earnings.","jir_og_title":"Sumitomo Pharma Posts JPY 48,340 Million Non-Operating Income in Standalone Financial Statements for Fiscal Year Ending March 2026","jir_og_description":"Sumitomo Pharma recorded dividend income of JPY 48,340 million from a consolidated subsidiary as non-operating income in its standalone financial statements for the fiscal year ending March 2026. No impact on consolidated earnings.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-36452","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n